Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)

Recruiting

Phase 1

Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)

Sponsor:

John Rieth

Code:

NCT06113809

Conditions

Undifferentiated Pleomorphic Sarcoma

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Palbociclib

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by John Rieth on 2024-07-26.